Barriers to the treatment of hepatitis C. Patient, provider, and system factors.
about
Burden of disease and cost of chronic hepatitis C infection in CanadaBarriers to hepatitis C treatmentRates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral CentersFactors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC StudyBest strategies for global HCV eradication.State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and ImmunizationModeling the Health and Economic Burden of Hepatitis C Virus in SwitzerlandA randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia.Context of clinical care: the case of hepatitis C in underserved communities--a report from the Primary Care Multiethnic Network (PRIME Net) Consortium.Patients' preferences for treatment of hepatitis CThe hepatitis C cascade of care: identifying priorities to improve clinical outcomesFactors that influence an HIV coinfected patient's decision to start hepatitis C treatmentAccess to healthcare insurance and healthcare services among syringe exchange program clients in Massachusetts: qualitative findings from health navigators with the iDU ("I do") Care Collaborative.Ending hepatitis C in the United States: the role of screening.Awareness of biologically confirmed HCV among a community residing sample of drug users in Baltimore City.Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France)Portraying persons who inject drugs recently infected with hepatitis C accessing antiviral treatment: a cluster analysis.Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting.Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsBarriers to accessing care in patients with chronic hepatitis C: the impact of depression.HCV infected prisoners: should they be still considered a difficult to treat population?Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidenceAssessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment.Provider Workforce Assessment in a Rural Hepatitis C Epidemic: Implications for Scale-up of Antiviral Therapy.Managing chronic hepatitis C in primary-care settings: more than antiviral therapyChronic hepatitis C: treat or wait? Medical decision making in clinical practicePatterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection.Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.Rate, delay and predictors of hepatitis C treatment in British ColumbiaCost-effectiveness and population outcomes of general population screening for hepatitis C.The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan.Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control studyPrimary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents.Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenanceIntegrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes.Evaluation of an integrated care service facility for people living with hepatitis C in New Zealand.Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department.Public health clinic-based hepatitis C testing and linkage to care in Baltimore.
P2860
Q26849591-CEDA99D1-EFA3-4386-8A14-3FCE4800D579Q27012664-7096E61D-7426-49E3-8D60-D87A1F94AFBBQ27491310-249C1EC1-6209-423D-8D30-CB2FD6835FA9Q27491349-393FDF7A-A7DC-440A-B21B-A823393117FEQ27693824-24D96053-2EF8-490F-A8D8-975BC477A980Q28079102-FCACE755-0494-4BC1-9282-D119F3FB4A7EQ28548657-C34D62B5-F73F-4EC7-AA9F-4791C17349B9Q30540697-843C8D11-8A40-418D-A1AA-71CF40437375Q33566074-E95E5C0B-53A1-4704-800B-A8EFF5336B39Q33591192-E09B57CA-46E1-4485-96BA-82B9A0FEC39EQ33615461-EE8C2021-39F9-45DA-89D4-9C2E1D6CD775Q33632459-A7D58574-A56B-42C4-B0D1-6CCCACBB5679Q33705645-1920B0C1-BB49-463C-8504-D713A02FD6F3Q33706376-B1DCC06E-A399-4130-94C7-D72648CB8F4DQ33862919-375BBFB6-E45C-4794-A681-D8F7CEE14E53Q34077806-E4A248EB-E747-4CE8-BC4B-791B0859F268Q34191840-48071D94-3A22-49EE-BCD9-65246891728EQ34348710-85AA6AB0-ACBE-4E1B-88D3-6F4159FFA55BQ34539238-BD21A792-76EB-48BD-A47F-21B621F068C3Q34735072-A772F892-BEAA-4311-9B3E-5FF271B71AAEQ34913362-A88DDEA3-2154-425E-9F69-DA578FD4DFBFQ34941459-B2561E56-6966-485A-81E5-48F7942AD67FQ35491398-0F81A23C-E98F-449F-B990-0D6E2ADFA743Q35540200-155597B4-A6EC-456E-A47F-E58A122C1AF9Q35634124-E562B418-BF46-4065-AF0D-3862EBC28E09Q35639889-A2641AD8-D2D8-4645-A9A6-B408AF6183D8Q35696990-6BD36848-71E6-411D-99DC-7B7A6B187DF2Q35872101-B6125181-94C5-4460-A9C9-AE55B9710641Q35905912-AB6DDBA6-515E-4134-A8BB-06218045DBF3Q36009124-1C51A394-839C-4EF9-9CB3-DA64B8A852B5Q36082161-F963126E-A2EB-4A61-A752-A3D3E96EA040Q36115516-9C9508BC-8F37-4645-A9F1-FDA12F6E6B70Q36185899-444DA4D3-B845-47D8-84E2-7F8F183834B7Q36296251-6D2F556F-3D65-4198-B54A-9233532AA719Q36353382-EEB1F463-A0BD-4A61-9A49-5A8490039430Q36562909-371A382F-95B8-46B5-A387-4E5A63A33E49Q36619642-C96D1A90-4108-4110-A26B-7698B131A50EQ36700770-05DF688E-2EA9-416C-9B1C-4293535F5D98Q36783216-DAD6D543-BD92-4764-989E-5F5FF408BC26Q36813466-7D37CF55-479B-4AF2-AD23-E236F59BEF6C
P2860
Barriers to the treatment of hepatitis C. Patient, provider, and system factors.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Barriers to the treatment of hepatitis C. Patient, provider, and system factors.
@ast
Barriers to the treatment of hepatitis C. Patient, provider, and system factors.
@en
Barriers to the treatment of hepatitis C. Patient, provider, and system factors.
@nl
type
label
Barriers to the treatment of hepatitis C. Patient, provider, and system factors.
@ast
Barriers to the treatment of hepatitis C. Patient, provider, and system factors.
@en
Barriers to the treatment of hepatitis C. Patient, provider, and system factors.
@nl
prefLabel
Barriers to the treatment of hepatitis C. Patient, provider, and system factors.
@ast
Barriers to the treatment of hepatitis C. Patient, provider, and system factors.
@en
Barriers to the treatment of hepatitis C. Patient, provider, and system factors.
@nl
P2093
P2860
P1476
Barriers to the treatment of hepatitis C. Patient, provider, and system factors.
@en
P2093
James A Morrill
Melissa Shrestha
Richard W Grant
P2860
P304
P356
10.1111/J.1525-1497.2005.0161.X
P577
2005-08-01T00:00:00Z
P5875
P6179
1002404968